

# Mengzhao Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6810328/publications.pdf>

Version: 2024-02-01

110  
papers

2,271  
citations

218381

26  
h-index

301761

39  
g-index

139  
all docs

139  
docs citations

139  
times ranked

3360  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study. PLoS ONE, 2015, 10, e0143515.	1.1	143
2	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16, 1512-1522.	0.5	127
3	&lt;p&gt;MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 2491-2510.	1.0	65
4	Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small cell lung cancer. Respiriology, 2016, 21, 519-525.	1.3	61
5	Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nature Communications, 2017, 8, 823.	5.8	53
6	EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. Cancer Chemotherapy and Pharmacology, 2016, 78, 1305-1310.	1.1	52
7	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thoracic Cancer, 2020, 11, 191-197.	0.8	52
8	Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. EBioMedicine, 2019, 42, 304-310.	2.7	51
9	Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster. Emerging Microbes and Infections, 2020, 9, 924-927.	3.0	51
10	PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. Future Oncology, 2018, 14, 665-674.	1.1	49
11	Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 209-216.	3.2	47
12	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. OncoTargets and Therapy, 2018, Volume 11, 6189-6196.	1.0	47
13	&lt;p&gt;Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 7707-7719.	0.9	45
14	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. Theranostics, 2016, 6, 1232-1243.	4.6	42
15	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thoracic Cancer, 2019, 10, 551-556.	0.8	42
16	CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. Future Oncology, 2018, 14, 2179-2188.	1.1	41
17	Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. Oncotarget, 2017, 8, 5861-5873.	0.8	41
18	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. Biomarker Research, 2021, 9, 79.	2.8	36

#	ARTICLE	IF	CITATIONS
19	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	1.4	35
20	Integrin Imaging with <sup>99m</sup> Tc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer. <i>Radiology</i> , 2016, 281, 958-966.	3.6	34
21	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016). <i>TJ ETQq1</i> 1.0, 784314. <i>rgBT /C</i> 0.7, 34	1.0	34
22	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , 2018, 125, 142-149.	0.9	34
23	Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death. <i>PLoS ONE</i> , 2015, 10, e0139144.	1.1	32
24	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	0.9	32
25	Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy. <i>Oncotarget</i> , 2017, 8, 86615-86624.	0.8	32
26	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 401-407.	0.9	31
27	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9008-9008.	0.8	30
28	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	7.7	30
29	Paraneoplastic limbic encephalitis associated with lung cancer. <i>Scientific Reports</i> , 2018, 8, 6792.	1.6	29
30	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 989-999.	1.3	28
31	Current small cell lung cancer treatment in China. <i>Thoracic Cancer</i> , 2015, 6, 233-238.	0.8	26
32	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	0.5	26
33	Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 640-645.	0.8	23
34	Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13136-45.	0.5	23
35	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020, 11, 810-818.	0.8	19
36	Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 219-227.	0.8	19

#	ARTICLE	IF	CITATIONS
37	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in <sc>China</sc>. Thoracic Cancer, 2022, 13, 412-422.	0.8	19
38	Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study. Thoracic Cancer, 2019, 10, 1521-1532.	0.8	18
39	Sputum Cell-Free DNA. Journal of Molecular Diagnostics, 2020, 22, 934-942.	1.2	18
40	Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. Frontiers in Immunology, 2021, 12, 619147.	2.2	18
41	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. Lung Cancer, 2018, 122, 1-6.	0.9	17
42	Management of immune checkpoint inhibitor-related dermatologic adverse events. Thoracic Cancer, 2020, 11, 488-492.	0.8	17
43	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. Cancer Biology and Medicine, 2019, 16, 189.	1.4	16
44	Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Thoracic Cancer, 2020, 11, 1955-1962.	0.8	16
45	Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thoracic Cancer, 2020, 11, 1068-1075.	0.8	15
46	The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 201-210.	0.7	15
47	Genomic characteristics of driver genes in <sc>Chinese</sc> patients with non-small cell lung cancer. Thoracic Cancer, 2021, 12, 357-363.	0.8	15
48	Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine. Future Oncology, 2019, 15, 2531-2542.	1.1	14
49	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic Cancer, 2020, 11, 594-602.	0.8	14
50	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. Translational Lung Cancer Research, 2021, 10, 4477-4493.	1.3	14
51	The Prevalence and clinical characteristics of primary Sjogren's syndrome patients with lung cancer: An analysis of ten cases in China and literature review. Thoracic Cancer, 2015, 6, 475-479.	0.8	13
52	PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours. Oncology Letters, 2017, 14, 1373-1378.	0.8	13
53	Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring <i>HER2</i> mutation: A case report and review of the literature. Thoracic Cancer, 2018, 9, 1788-1794.	0.8	13
54	Efficacy of icotinib in advanced lung squamous cell carcinoma. Cancer Medicine, 2018, 7, 4456-4466.	1.3	13

#	ARTICLE	IF	CITATIONS
55	Clinical recommendations on lung cancer management during the COVID-19 pandemic. <i>Thoracic Cancer</i> , 2020, 11, 2067-2074.	0.8	13
56	Clinical characteristics of patients with lung cancer and idiopathic pulmonary fibrosis in China. <i>Thoracic Cancer</i> , 2012, 3, 156-161.	0.8	11
57	Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000823.	2.0	11
58	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1689-1694.	0.8	11
59	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	2.2	11
60	A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3089-3089.	0.8	11
61	Programmed cell death 1 (PD-1)/PD-L1 inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 299-304.	0.7	10
62	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	0.8	10
63	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. <i>Thoracic Cancer</i> , 2020, 11, 793-796.	0.8	10
64	Clinicopathological features of lung cancer in patients with rheumatoid arthritis. <i>Journal of Thoracic Disease</i> , 2018, 10, 3965-3972.	0.6	9
65	Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. <i>Targeted Oncology</i> , 2019, 14, 325-333.	1.7	9
66	Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers. <i>Oncologist</i> , 2022, 27, 342-e383.	1.9	8
67	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 1056-1061.	0.8	7
68	Thymic neoplasms patients complicated with bronchiectasis: Case series in a Chinese hospital and literature review. <i>Thoracic Cancer</i> , 2019, 10, 791-798.	0.8	7
69	Pituitary Involvement in Granulomatosis with Polyangiitis: A Retrospective Analysis in a Single Chinese Hospital and a Literature Review. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-9.	0.6	7
70	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	7
71	Prognostic impact of maximum standardized uptake value on 18 F-FDG PET / CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2021, 12, 845-853.	0.8	7
72	Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. <i>Thoracic Cancer</i> , 2021, 12, 2825-2828.	0.8	7

#	ARTICLE	IF	CITATIONS
73	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. Journal of Clinical Oncology, 2017, 35, e20613-e20613.	0.8	7
74	Integrated positron emission tomography and computed tomography in preoperative lymph node staging of non-small cell lung cancer. Chinese Medical Journal, 2014, 127, 607-13.	0.9	7
75	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. OncoTargets and Therapy, 2018, Volume 11, 7513-7519.	1.0	6
76	Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. Clinical Respiratory Journal, 2020, 14, 1131-1136.	0.6	6
77	Renal immune-related adverse events of immune checkpoint inhibitor. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 305-311.	0.7	6
78	Recognition and management of the gastrointestinal and hepatic immune-related adverse events. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 95-102.	0.7	6
79	Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR TKIs. Cancer Medicine, 2021, 10, 3323-3331.	1.3	6
80	International consensus on severe lung cancer—the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	1.3	6
81	Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. Thoracic Cancer, 2021, 12, 2339-2344.	0.8	6
82	Value and significance of brain radiation therapy during first-line EGFR TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. Thoracic Cancer, 2021, 12, 3157-3168.	0.8	6
83	Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. Thoracic Cancer, 2021, , .	0.8	6
84	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. Journal of Clinical Oncology, 2022, 40, 9015-9015.	0.8	6
85	Detection of low-level DNA mutation by ARMS-blocker-Tm PCR. Clinical Biochemistry, 2016, 49, 287-291.	0.8	5
86	Pulmonary hypertension associated with combined fibrosing mediastinitis and bronchial anthracofibrosis: A retrospective analysis in a single Chinese hospital. Clinical Respiratory Journal, 2018, 12, 1134-1140.	0.6	5
87	Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib. Thoracic Cancer, 2019, 10, 1213-1219.	0.8	5
88	Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. Oncotarget, 2017, 8, 86969-86984.	0.8	5
89	Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 481-488.	0.7	5
90	Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. Cancer Management and Research, 2019, Volume 11, 8191-8200.	0.9	4

#	ARTICLE	IF	CITATIONS
91	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA—Lung study). <i>Thoracic Cancer</i> , 2018, 9, 1795-1800.	0.8	3
92	<i>ALK</i> -rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report. <i>Thoracic Cancer</i> , 2018, 9, 1078-1081.	0.8	3
93	IgG4-related disease can present as recurrent spontaneous hemothorax: a case report. <i>BMC Pulmonary Medicine</i> , 2019, 19, 26.	0.8	3
94	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum—pemetrexed: The first report of two cases. <i>Thoracic Cancer</i> , 2020, 11, 2339-2342.	0.8	3
95	Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21072-e21072.	0.8	3
96	Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). <i>Cancer Research</i> , 2021, 81, CT041-CT041.	0.4	3
97	Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study. <i>Thoracic Cancer</i> , 2022, 13, 1684-1690.	0.8	3
98	An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8039-8039.	0.8	2
99	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1059-1066.	0.8	2
100	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor—associated adverse events. <i>Thoracic Cancer</i> , 2020, 11, 2077-2086.	0.8	1
101	EGFR mutation status in cerebrospinal fluid of NSCLC patients who developed leptomeningeal metastasis after EGFR-TKI treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8081-8081.	0.8	1
102	Effect of abundance of EGFR activating mutations and presence of T790M mutation in TKIs-naive tumor specimen on gefitinib response duration in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19077-e19077.	0.8	1
103	Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage I non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20531-e20531.	0.8	1
104	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9077-9077.	0.8	1
105	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2022, 166, 98-106.	0.9	1
106	Immunohistochemistry to detect EGFR mutation and ALK gene rearrangement in NSCLC bronchoscopic specimens.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19135-e19135.	0.8	0
107	The pathway of PI3K/AKT/mTOR in pulmonary carcinoids.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22185-e22185.	0.8	0
108	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19070-e19070.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.. Journal of Clinical Oncology, 2019, 37, e20513-e20513.	0.8	0
110	Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study. Frontiers in Oncology, 2022, 12, 879554.	1.3	0